Cannabidiol for Dravet and Lennox-Gastaut syndromes: NICE guidance

Abstract

Recent NICE guidance on the use of cannabidiol for two rare epilepsy syndromes could be seen as a crucial step in the acceptance of a medical role for cannabis derivatives. Formal trial evidence and official recommendation for the use of what has been regarded by many as a controversial substance for medicinal use should help those who may derive benefit to access it.